araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: 2D Strain of Right Ventricle in Peroperative of Cardiac Surgery

Summary: Evaluation of the right ventricle (RV) deformation (strain) with 2D speckle tracking technics obtained by echocardiographies (TEE) in peroperative period of cardiac surgery .
  TEE is performed for each patient of cardiac surgery during the operation time .
  This new evaluation parameter of RV could be a good tool to assess the early RV dysfunction after cardiac surgery.

Detailed description: Monitoring of 2D strain of right ventricle free wall by TEE in perioperative of cardiac surgery :
  In preoperative time After sternotomy After surgery Inclusions of patients elected for aortic valve surgery without coronary diseases or previous RV dysfunction.
  Comparison with others echocardiographic parameters of RV evaluation Association with right ventricle insufficiency after cardiac surgery.

Eligibility: Inclusion Criteria:
  -  patient eligible for aortic valve surgery
  Exclusion criteria:
  -  previous right ventricle dysfunction
  -  severe coronary disease

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)

Summary: Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.


Eligibility: Retrospective
  Inclusion Criteria:
  Subjects who met the American College of Rheumatology 1990 classification criteria for Takayasu arteritis:
  1. Age of onset ≤40 years,
  2. Claudication of upper or lower extremities,
  3. Decreased pulsation of 1 or both brachial arteries,
  4. Difference of ≥ 10 mmHg in systolic blood pressure between arms,
  5. Bruit over subclavian arteries or aorta,
  6. *Arteriographic evidence showing a branch of the aorta stenosis or occlusion.
  Meeting more than 3 of 6 criteria suggests the diagnosis of Takayasu arteritis.
  *Angiography in this study was replaced by vascular magnetic resonance angiography(MRA)or computed tomography angiography(CTA).
  Exclusion Criteria:
  1. Arteriographic lesions that could be entirely due to atherosclerosis,
  2. Suffer from other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.) besides Takayasu arteritis,
  3. Cogan's syndrome,
  4. Behcet's disease,
  5. Subjects with any serious acute or chronic infection,
  6. Giant cell arteritis (large vessel vasculitis and at least 50 years old) or other infectious forms of large vessel vasculitis.
  Prospective
  Inclusion Criteria:
  Subjects with initial suspicion of having Takayasu arteritis or patients with Takayasu arteritis need assessment of disease activity were prospectively enrolled.
  Exclusion Criteria:
  1. Patients without image studies.
  2. Patients with confirmed other autoimmune diseases (eg, ANCA-associated vasculitis, systemic lupus erythematosus, etc.)

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Obstructive Sleep Apnoea in Adolescents With Thoracic Aortic Aneurysm

Summary: The objective of this prospective cohort study is to determine the prevalence of obstructive sleep apnoea (OSA) in patients with and without thoracic aortic aneurysm.

Detailed description: The objective of this prospective cohort study is to determine the prevalence of obstructive sleep apnoea (OSA) in patients with and without thoracic aortic aneurysm.

Eligibility: Inclusion Criteria:
  -  Age > 18 years.
  -  Diagnosis of thoracic aortic aneurysm defined by the following parameters:
  Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. (for controls: <39mm and <42mm respectively); Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm. (for controls: <44mm and <46mm respectively)
  Exclusion Criteria:
  -  Patients on continuous positive airway pressure (CPAP) therapy for OSA at baseline.
  -  Patients with known central sleep apnoea.
  -  Patients on morphine or other opioid medication, heroin addiction, alcohol addiction.
  -  Patients with moderate or severe aortic regurgitation.
  -  Patients with moderate or severe aortic stenosis.
  -  Pregnant patients.

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH

Summary: This study explore AAA prevalence in OSAHS patients by ultrasound screening and try to analysis risk factors of AAA in OSAHS patients.

Detailed description: Abdominal aortic aneurysm (AAA) is an extremely high mortality disease, and ultrasound has been recommended for the screening of AAA, which is highly sensitive and specific. Studies have shown that screening for AAA in the population can significantly reduce deaths from ruptured abdominal aortic aneurysms. However, those study mainly focus on cardiovascular disease patients or general population, no previous study target on obstructive sleep apnea hypopnea syndrome (OSAHS) population. Retrospective studies show that the incidence of apnea syndrome in patients with abdominal aortic aneurysm is higher than that in the control group, which suggests that OSAHS may be one of the causes of abdominal aortic aneurysm. At present, there is no relevant research on the screening of AAA in OSAHS population.
  The main objective of this study was to screen the prevalence of AAA in OSAHS population by a cross-sectional study.

Eligibility: Inclusion Criteria:
  -  All patients who accept respiratory sleep monitoring in the department of ENT, BTCH, aged over 45 years, from 2018-01-01 to 2019-12-30
  Exclusion Criteria:
  -  1. Any previous diagnosis of AAA history;
  -  2. Received AAA related treatment;
  -  3. Past imaging test result suggested increased diameter of the abdominal aorta.
  -  4. Poor compliance; refused to follow the requirements set in this study follow-up, and refused to sign informed consent.

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Clinical Outcomes and Quality of Life Measures in Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms

Summary: This is a prospective, non-randomized, single center, data collection study of patients treated with open surgical repair (OR) for complex aortic aneurysms (CAAs).


Eligibility: Inclusion Criteria:
  Patients undergoing elective, emergent or urgent OR for CAAs, including:
  1. Abdominal aortic aneurysms (AAA) not eligible for endovascular aneurysm repair (EVAR), including 1) Infrarenal AAA with complex aneurysm morphology 2) Short neck infrarenal AAA 3) Juxtarenal AAA 4) Suprarenal AAA
  2. Thoracoabdominal aortic aneurysms (TAAA) (Type I - IV)
  3. Chronic aortic dissections
  Exclusion Criteria:
  1. Patients who refuse to participate the study
  2. Patients age < 18 years
  3. Pregnant breastfeeding patients

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms

Summary: The primary objective of this research project is development and validation of a new, non-contrast gated aortic (NCGA) computer tomography scan algorithm for screening of aortic aneurysm in the chest and abdomen in at risk patients. This study would initially be performed in patients with a known aneurysm and done in addition to their indicated surveillance CT scan.

Detailed description: Study Design: Patients who agree to enroll in the study will get the NCGA study as well as a routine non-contrast computed tomography of chest/abdomen/pelvis within one year following recruitment at the patient's convenience. No follow-up will be required, but any clinically relevant findings on the testing will be communicated to the PCP through EPIC in-basket. Urgent findings, as determined by the primary investigator, will also result in a direct communication with the PCP. It is expected that any such findings will also be seen on the standard and clinically indicated CT which they are also undergoing, and so "new or unique" findings on the study NCGA test are not expected to occur. The final study visit will be the day of participation.
  Study Design: Patients who agree to enroll in the study will get the NCGA study as well as a routine non-contrast computed tomography of chest/abdomen/pelvis within one year following recruitment at the patient's convenience. No follow-up will be required, but any clinically relevant findings on the testing will be communicated to the PCP through EPIC in-basket. Urgent findings, as determined by the primary investigator, will also result in a direct communication with the PCP. It is expected that any such findings will also be seen on the standard and clinically indicated CT which they are also undergoing, and so "new or unique" findings on the study NCGA test are not expected to occur. The final study visit will be the day of participation.
  Study Procedures: One visit to complete one (1) non-contrast (no "dye"/contrast material will be injected) computed tomography (CT) scan of the chest, abdomen and pelvis. This visit will occur within one year following recruitment, scheduled at the patient's convenience. This one visit represents the totality of study participation for each participant.
  Study Duration: For each individual, participation is only over one day - the day of the patient's non-contrast CT scan. No early termination visits or unscheduled visits apply.
  The anticipated duration to complete enrollment of all participants is 1 year. Following completion of the study, the study team is planning for an interim period of 6 months for discussion and planning for future projects.

Eligibility: Inclusion Criteria:
  -  Adult patients who carry the diagnosis of thoracic aortic aneurysm, aortic dissection, or abdominal aortic aneurysm and require CT imaging to evaluate the pathology
  Exclusion Criteria:
  -  Current pregnancy

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Assessment of Diastolic Function in High Risk Patients Undergoing Major Vascular Surgery

Summary: Patients scheduled for Thoracic Endovascular Aortic Repair (TEVAR) surgery will have transthoracic echocardiography evaluation of left ventricle diastolic function during the perioperative period.

Detailed description: Patients undergoing TEVAR surgery are a high risk group of developing perioperative cardiovascular complications.
  Left ventricle diastolic dysfunction is common in this group of patients because of the prevalence of risk factors: > 60 years old, hypertension, smoking history and diabetes.
  Because of many predisposing factors that occur during the surgery: stress respond, fluid shifts, anaesthesia and mechanical ventilation. Deterioration of the diastolic function is likely to occur in perioperative period
  In this study, the investigators will evaluate change in left ventricle diastolic function as a marker for early detection of a myocardial failure in patients scheduled for an elective TEVAR surgery. The examination will be performed preoperatively, shortly after the surgery and 24 hours after the surgery.
  Aim: The aim of the study is to evaluate the diastolic function of left ventricle in perioperative period after high risk surgery. This may provide a valuable information in preoperative risk stratification and postoperative therapy guidance.

Eligibility: Inclusion Criteria:
  -  scheduled TEVAR
  -  >60 years old
  Exclusion Criteria:
  -  Atrial fibrillation or other non-sinus rhythms
  -  Atrioventricular blocks
  -  Heart rate change more than 25% postoperatively
  -  Not adequate transthoracic view
  -  Postoperative shock
  -  Sepsis

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Does Urinary TIMP2 and IGFBP7 Can Identify High Risk Patients of Progression From Mild and Moderate to Severe Acute Kidney Injury During Septic Shock?

Summary: Septic shock is one of the leading causes of death in patients admitted to the intensive care unit (ICU). Acute kidney injury (AKI) occurs in almost 50% of septic patients and is associated with significant mortality. Progression to the last stage (KDIGO stage 3) of AKI is an important step in the disease, as it usually requires initiation of RRT. Renal biomarkers are unable to accurately identify those patients who will progress to severe AKI (KDIGO 3). However, identification of patients at risk of progression to severe AKI could help the clinician to initiate optimal therapy including RRT. A new urine test, the Nephrocheck™ corresponding to the product of the urinary concentrations of 2 markers of renal tubule injury (TIMP2 and IGFBP7) has been validated. The Investigator have already performed two previous studies including septic shock patients (AKICHECK and BIOOCHECK). those previous datas will be reanalysed to examine whether the new urinary biomarkers TIMP2 and IGFBP7 can predict progression within 24 hours and 72 hours from mild and moderate (KDIGO 1 or 2) to severe AKI (KDIGO 3) in patients with septic shock.
  -All the datas required will be collected from two previous studies (AKICHECK and BIOCHECK) performed in 3 centers: Amiens medical ICU, Melun medico surgical ICU and Montpellier Medical ICU.


Eligibility: Inclusion Criteria:
  -  Age 18 or over
  -  Septic shock (according to Bone's criteria) within 4 hours of introduction of catecholamines
  -  AKI, characterized by a KDIGO score ≥ 1
  -  Social security coverage
  Exclusion Criteria:
  -  AKI requiring emergency RRT (in the critical care physician's opinion).
  -  Anuria
  -  Stage 4-5 chronic kidney failure with a GFR below 30 ml/min.
  -  Rapidly progressing renal disorders (glomerulonephritis, HUS, blockage, etc.)
  -  Obstructive AKI
  -  Probable glomerular damage (nephritic syndrome, nephrotic syndrome, chronic glomerulonephritis)
  -  Pregnancy or breastfeeding
  -  Legal guardianship or lack of social security coverage.
  -  Cardiocirculatory arrest
  -  Life expectancy <48 hours.
  -  Child C cirrhosis
  -  Prior occurrence of AKI during the current hospital stay
  -  Transplantation
  -  Subject participating in another study with an exclusion period ongoing at the time of the pre-inclusion

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Summary: This study was designed to explore the efficacy and safety of Crizotinib as a first-line treatment for advanced NSCLC with ROS1 rearrangement positive mutation in the real world, explore the new drug resistance mechanism of ROS1 under Crizotinib treatment and the consistency of plasma and tissue detection driving genes, and finally evaluate the mutation spectrum of plasma dynamic detection driving genes. In predicting the risk of disease progression.

Detailed description: This is a research project involving patients in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University. Retrospective study of 40 patients with advanced non-squamous non-small cell lung cancer (NSCLC) using Crizotinib ROS1 rearrangement positive mutation was conducted to observe the efficacy and safety of Crizotinib regimen in the real world.Exploratory research contents are as follows: 1. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial diagnosis; 2. Consistency between NGS and plasma gene test (NGS) at the progression of clozotinib treatment; 3. Drug resistance mechanism of clozotinib in ROS1 rearrangement positive NSCLC; 4. Plasma drug resistance. Large panel dynamic driven gene mutation analysis was used to construct disease progression risk model.

Eligibility: Inclusion Criteria:
  -  ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
  -  ROS1 Arranged Positive
  -  ROS1 Arranged Detection Method is NGS
  -  First Diagnosis and Treatment
  -  Treatment Plan is Kazolinib 250mg po bid
  Exclusion Criteria:
  -  Patients received antitumor treatment before
  -  Patients with contraindication of chemotherapy
  -  Pregnant or breast feeding women

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae

Summary: The study compares the efficacies of two surgical procedures for the treatment of mitral valve prolapse due to myxomatous degeneration of the mitral valve: the chordae replacement and the translocation of secondary mitral valve chordae.

Detailed description: Summary: This study compares the efficacy and the safety of two surgical procedures for the treatment of mitral valve prolapse due to degeneration of the mitral valve: chordae replacement and the translocation of secondary mitral valve chordae.
  In our study, researchers used the loop method proposed by von Oppel and Mohr in 2000. The main principle of the method of prosthetic chordae is the preservation of the native anatomy of the mitral valve. This principle is achieved by the implantation of artificial chordae made of ePTFE Gore-Tex threads.
  The chordae replacement method essentially involves five stages:
  1. Measuring the required length of the chordae.
  2. Forming the loops.
  3. Fixation of the group of loops to the papillary muscles.
  4. Fixation of the chordal loops to the free edge of the valve.
  5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse.
  Chordae translocation is the alternative method, which does not require measurement and selection of chordae lengths. Chordae replacement is technically easier (less aortic clamping time) with comparable results.
  The technique of translocation of secondary chordae essentially consists of three stages:
  1. Selection of the secondary chordae.
  2. Fixation of secondary chordae to the free edge of the valve.
  3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse.

Eligibility: Inclusion Criteria:
  1. Isolated type II mitral valve insufficiency by A. Carpentier
  2. Mitral regurgitation degree >2
  3. Age >18 years
  4. Signed informed consent to participate in the study
  Exclusion Criteria:
  1. Any other cardiac surgeries
  2. Age <18 years
  3. Multiple organ failure
  4. ReDo procedure
  5. Persistent atrial fibrillation
  6. Acute infective endocarditis
  7. Refusal to sign informed consent

Relevance to patient case: not relevant
Patient case: 63-year-old female with aortic aneurysm; genetic feature: ACTA2

Clinical trial: Safety and Efficacy Study of Iliac Bifurcation Stent Graft System

Summary: A prospective, multi-centre, single-arm clinical trial to evaluate the safety and efficacy of Iliac Bifurcation Stent Graft System.

Detailed description: A prospective, multi-center, Single-Arm clinical trial to evaluate the safety and efficacy of endovascular treatment of the aortoiliac aneurysm or the iliac aneurysm by using Iliac Bifurcation Stent Graft System manufactured by Lifetech Scientific (Shenzhen) Co., LTD. According to the requirements of the study, 64 patients preoperatively diagnosed with the aortoiliac aneurysm or the iliac aneurysm will be recruited and be treated by Iliac Bifurcation Stent Graft System under the guidance of aortic aortography. The safety of operations, stability of releasing stent and the accuracy of positioning will be evaluated intraoperatively. The safety and efficacy of aortic endovascular treatment of Iliac Bifurcation Stent Graft System will be observed by postoperative follow up scheduled 30 days and 180 days after the operation.

Eligibility: Inclusion Criteria:
  1. Older than 18 years of age.
  2. The subject or its legal representative sign the informed consent.
  3. Patients with the aortoiliac aneurysm or the iliac aneurysm and need to endovascular restructure the internal iliac artery.
  4. The anatomical structure of the iliac artery meets the following requirements:
  1. The length of the anchoring zone of the external iliac artery is ≥15mm.
  2. The diameter of the anchoring zone of the external iliac artery is between 7mm and 12mm.
  3. The diameter of the external iliac artery is between 6mm-10mm.
  4. The length of the anchoring zone of the internal iliac artery is ≥10mm.
  5. Life expectancy is longer than one year.
  Exclusion Criteria:
  1. The patient is under 18 years old.
  2. Pregnant or lactating woman.
  3. The patient had a myocardial infarction or stroke within 3 months.
  4. The patient had connective tissue disease, infectious aneurysm, and other active infections.
  5. The patient has abdominal aortic aneurysm rupture.
  6. The patient has a severe coagulation disorder.
  7. Allergic to the material of stent or contrast media.
  8. Patient's vascular morphology is not suitable for endovascular repairs, such as serious stricture, dilate, bend, sclerosis, etc. of the iliac artery.
  9. Patients with severe mural thrombus in the aneurysm cavity, which may affect the implantation of Branch Stent.

Relevance to patient case: not relevant